High-risk and relapsed neuroblastoma: toward more cures and better outcomes
SG DuBois, ME Macy, TO Henderson - American Society of Clinical …, 2022 - ascopubs.org
Approximately half of the patients diagnosed with neuroblastoma are classified as having
high-risk disease. This group continues to have inadequate cure rates despite multiagent …
high-risk disease. This group continues to have inadequate cure rates despite multiagent …
[HTML][HTML] Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: Phase 1 trial results
…, R Mody, DA Morgenstern, S Shusterman, ME Macy… - Nature medicine, 2023 - nature.com
Neuroblastomas harbor ALK aberrations clinically resistant to crizotinib yet sensitive pre-clinically
to the third-generation ALK inhibitor lorlatinib. We conducted a first-in-child study …
to the third-generation ALK inhibitor lorlatinib. We conducted a first-in-child study …
Opportunities and challenges in drug development for pediatric cancers
TW Laetsch, SG DuBois, JG Bender, ME Macy… - Cancer discovery, 2021 - AACR
… ME Macy reports other from Johnson & Johnson (stockholder) outside the submitted work.
L. Moreno reports other from Novartis [Consultancy role and Member of DMC (fees to …
L. Moreno reports other from Novartis [Consultancy role and Member of DMC (fees to …
Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051) …
…, W Nicholls, E Fox, SG DuBois, ME Macy… - The Lancet …, 2020 - thelancet.com
Background Pembrolizumab is approved for the treatment of advanced cancer in adults;
however, no information is available on safety and efficacy in paediatric patients. We aimed to …
however, no information is available on safety and efficacy in paediatric patients. We aimed to …
Entrectinib and other ALK/TRK inhibitors for the treatment of neuroblastoma
HL Pacenta, ME Macy - Drug design, development and therapy, 2018 - Taylor & Francis
RTK plays important roles in many cellular signaling processes involved in cancer growth
and development. ALK, TRKA, TRKB, TRKC, and ROS1 are RTKs involved in several …
and development. ALK, TRKA, TRKB, TRKC, and ROS1 are RTKs involved in several …
Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG)
…, GW Robinson, K Gauvain, EM Basu, ME Macy… - Neuro …, 2022 - academic.oup.com
… Margaret E Macy , Margaret E Macy … Ami V Desai, Giles W Robinson, Karen Gauvain, Ellen
M Basu, Margaret E Macy, Luke Maese, Nicholas S Whipple, Amit J Sabnis, Jennifer H Foster…
M Basu, Margaret E Macy, Luke Maese, Nicholas S Whipple, Amit J Sabnis, Jennifer H Foster…
Molecular profiling identifies targeted therapy opportunities in pediatric solid cancer
To evaluate the clinical impact of molecular tumor profiling (MTP) with targeted sequencing
panel tests, pediatric patients with extracranial solid tumors were enrolled in a prospective …
panel tests, pediatric patients with extracranial solid tumors were enrolled in a prospective …
Phase 1/1B trial to assess the activity of entrectinib in children and adolescents with recurrent or refractory solid tumors including central nervous system (CNS) tumors …
…, AJ Gajjar, KM Gauvain, EM Basu, ME Macy… - 2019 - ascopubs.org
10009 Background: Entrectinib is a CNS-penetrant oral inhibitor of TrkA/B/C, ROS1 and
ALK tyrosine kinases. We report the efficacy of entrectinib in children with recurrent/refractory …
ALK tyrosine kinases. We report the efficacy of entrectinib in children with recurrent/refractory …
Phase II trial of alisertib in combination with irinotecan and temozolomide for patients with relapsed or refractory neuroblastoma
…, MM Granger, B Weiss, JR Park, ME Macy… - Clinical Cancer …, 2018 - AACR
Purpose: In phase I testing, alisertib tablets with irinotecan and temozolomide showed significant
antitumor activity in patients with neuroblastoma. This study sought to confirm activity of …
antitumor activity in patients with neuroblastoma. This study sought to confirm activity of …
[HTML][HTML] CFEOM3: a new extraocular congenital fibrosis syndrome that maps to 16q24. 2-q24. 3
EJ Doherty, ME Macy, SM Wang… - … & visual science, 1999 - arvojournals.org
purpose. To define the clinical characteristics and determine the gene localization for a
previously undescribed form of congenital fibrosis of the extraocular muscles (CFEOM), referred …
previously undescribed form of congenital fibrosis of the extraocular muscles (CFEOM), referred …